Pharmafile Logo

MAKING THE FIRST YEAR MATTER

October 26, 2021 |  

*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded a ‘Communique’ award for ‘Excelling in multi-channel campaigns’ for its work with CSL Behring, alongside six further award commendations and wins  *The agency offers a ‘health first, sector second’ approach with access to sector experts with unparalleled breadth and depth of capabilities *The growth has led to more than 60 new hires globally, and senior promotions to the UK leadership team alongside the launch of Gravity.ai – a first of its kind global healthcare intelligence data platform

Mind+Matter(an Ashfield Health company, part of UDG Healthcare), a ‘global creative powerhouse in health’ is celebrating its first year of business after securing more than £4 million in new business revenue across key strategic wins that span pharma, medical devices, consumer and animal health clients.

Since the launch of its new proposition in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing, the UK Mind+Matter team, led by Corrina Safeio, has gone from strength to strength, drawing on the expertise of its world-class experts based globally.

New senior roles include the promotion of Ian Rayfrom Associate Creative Director to Creative Director, and Kesha Tansey to Client Director. Ian and Kesha join the UK Mind+Matter leadership team and will pay a key role in shaping the future strategy and direction of the agency.

Safeio says it’s already very clear by the raft of new business wins that the health sector needs a deeply interconnected, cross-sector response to both existing clients and new client challenges.

“It’s been a phenomenal first year for Mind+Matter and I’m extremely proud of our talented team and what we have been able to accomplish together. Creating meaningful experiences by bringing data and emotion together to drive behaviour change is at the heart of what we do, day in day out. It’s this proposition alongside our health first, sector second approach that has chimed most with clients –existing and new.”

At the heart of the Mind+Matter offer is CHANGE, a behavioural science-led strategic methodology co-created with the internationally recognised Centre for Behaviour Change at University College London (itself an expert voice in the public health response to Covid-19).

In its first year, Mind+Matter also launched Gravity.ai a first of its kind global healthcare intelligence data platform. Gravity.ai incorporates artificial intelligence, predictive analytics, data modelling and scientific human consultancy to better understand audiences, behaviour and channel performance, ensuring clients get the best value for their investment.

Safeio adds: “Covid has shown how our individual health is also a truly global issue and personalised communications have never been more important. Matched with our deep earned, owned and paid expertise, Gravity.ai allows us to discover meaningful links between demographics, technologies, and customer behaviours and track the changing dynamics of HCP, patient and consumer communications in a rapidly shifting digital world. This powers our planning model CHANGE, along with proven behavioural science. It’s powerful stuff that delivers impactful, measurable results.”

Ben Beckley leads the new agency from Boston in the US, along with Managing Directors Corrina Safeio and Carina Whitridge, who head up the EMEA and US regions respectively.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

PEGASUS JOINS ASHFIELD HEALTHCARE COMMUNICATIONS

Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider...

Living with Crohn’s Report

Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?

Infographic: Research Partnership

Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.

AAD conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016

Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...

What we do and who we do it for | Pegasus

We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital...

Understanding decision making in health | Pegasus

To reflect the importance of self-care in health, we developed and launched a new model for exploring personal health decision-making which provides a framework for strategic planning, whatever the therapy...